{"id":732730,"date":"2023-02-20T08:03:20","date_gmt":"2023-02-20T13:03:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/"},"modified":"2023-02-20T08:03:20","modified_gmt":"2023-02-20T13:03:20","slug":"new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/","title":{"rendered":"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology"},"content":{"rendered":"<h2>\nFeatured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">THE WOODLANDS, Texas, Feb.  20, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w8itCOB04hf67YkrRUMFR7_5EG637DpDRSVYUj6pddd8vOPDy9onjRYE9iW9jzX7_-MQAarZZ28JiPKAOFm9sbhqIO6Y08FlNFSzoFbXUVw=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Lexicon Pharmaceuticals, Inc.<\/u><\/a> (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology\u2019s 72<sup>nd<\/sup> Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology in New Orleans, Louisiana.<\/p>\n<p align=\"justify\">The following analyses of sotagliflozin have been selected for presentation:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10674\/presentation\/11625\" rel=\"nofollow noopener\" target=\"_blank\">\u201cTime to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF\u201d<\/a>, a moderated poster presentation on Saturday, March 4<sup>th<\/sup> at 11:00 am CT<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10674\/presentation\/11624\" rel=\"nofollow noopener\" target=\"_blank\">\u201cEffects of SGLT 1-2 Inhibitor Sotagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients with Worsening Heart Failure: Results from the SOLOIST Trial\u201d<\/a>, a moderated poster presentation on Saturday, March 4<sup>th<\/sup> at 10:15 am CT<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10674\/presentation\/19568\" rel=\"nofollow noopener\" target=\"_blank\">\u201cLevels of Soluble Urokinase Plasminogen Activator Receptor and Heart Failure Outcomes in Patients with Type 2 Diabetes and Worsening Heart Failure Treated with Sotagliflozin, a Dual SGLT 1 and SGLT 2 Inhibitor\u201d<\/a>, a poster presentation on Sunday, March 5<sup>th<\/sup> at 2:45 pm CT<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10674\/presentation\/11363\" rel=\"nofollow noopener\" target=\"_blank\">\u201cSotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Atheroprotective Proteins during Inflammation Compared with Empagliflozin\u201d<\/a>, a moderated poster presentation on Monday, March 6<sup>th<\/sup> at 10:30 am CT<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About the SOLOIST-WHF Study<\/strong>\n      <\/p>\n<p align=\"justify\">SOLOIST-WHF was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.<\/p>\n<p align=\"justify\">SOLOIST-WHF achieved its primary endpoint, with overall tolerability similar to placebo. Results were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in <em>The New England Journal of Medicine (NEJM)<\/em> in an article titled: \u201cSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure\u201d which may be accessed at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ueqWrpI5Z_fWrl0CWbFg48tVvOu8MNZFQijSbvobiYpKT3YLF_OSC7d11zsH2lOOyu4JL-u6M0tllIFbG-SqVQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.nejm.org<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Sotagliflozin <\/strong>\n      <\/p>\n<p align=\"justify\">Discovered using Lexicon\u2019s unique approach to gene science, sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, type 1 and type 2 diabetes, and chronic kidney disease in fourteen Phase 3 clinical studies involving approximately 20,000 patients.<\/p>\n<p align=\"justify\">\n        <strong>About Lexicon Pharmaceuticals <\/strong>\n      <\/p>\n<p align=\"justify\">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients\u2019 lives. Through its Genome5000\u2122 program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zDxU-6kW_n6HJm0ClqYJkvqlsHPuxcuG6soybYH6idB0fwhl_eZx_upZS1Esgdj99M8DZWR7w4UDmdm0BS2Sgg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.lexpharma.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains \u201cforward-looking statements,\u201d including statements relating to the research and clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin. In addition, this press release also contains forward looking statements relating to Lexicon\u2019s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management\u2019s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon\u2019s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon\u2019s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under \u201cRisk Factors\u201d in Lexicon\u2019s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>For Investor Inquiries<\/strong>:<\/p>\n<p align=\"justify\">Carrie Siragusa<br \/>Lexicon Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NnVl8N3et_zW3RrtqQ1H6xIsmpBKjud4tHBafkZUe4qnQONP4v_iqihANZZXPyjqtlg7oyeAwiCTRNRSqtVfF5qppA7IS29sZ805jQ1jfIY=\" rel=\"nofollow noopener\" target=\"_blank\">csiragusa@lexpharma.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>For Media Inquiries<\/strong>:<\/p>\n<p align=\"justify\">Alina Kolomeyer<br \/>Lexicon Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iMIybOamO1qxC1BNMEn-WlLV0UFvD7lj6pFclArH327mggSZrATt291wqWHHWkm7fLi8EHzugHMVTALPaGlbOLc6EqNqWWeRuVmPhpUaDNA=\" rel=\"nofollow noopener\" target=\"_blank\">akolomeyer@lexpharma.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWNlMTgwNjYtNGFjMy00N2ZmLWE3YWYtMTFkODE3MDVjNDU2LTEwMTU1NDA=\/tiny\/Lexicon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure THE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology in New Orleans, Louisiana. The following analyses of sotagliflozin have been selected for presentation: \u201cTime to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF\u201d, a moderated poster presentation on Saturday, March 4th at 11:00 am CT \u201cEffects of SGLT 1-2 Inhibitor Sotagliflozin on Symptoms, Physical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732730","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure THE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology in New Orleans, Louisiana. The following analyses of sotagliflozin have been selected for presentation: \u201cTime to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF\u201d, a moderated poster presentation on Saturday, March 4th at 11:00 am CT \u201cEffects of SGLT 1-2 Inhibitor Sotagliflozin on Symptoms, Physical &hellip; Continue reading &quot;New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T13:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology\",\"datePublished\":\"2023-02-20T13:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/\"},\"wordCount\":847,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/\",\"name\":\"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=\",\"datePublished\":\"2023-02-20T13:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/","og_locale":"en_US","og_type":"article","og_title":"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology - Market Newsdesk","og_description":"Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure THE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology in New Orleans, Louisiana. The following analyses of sotagliflozin have been selected for presentation: \u201cTime to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF\u201d, a moderated poster presentation on Saturday, March 4th at 11:00 am CT \u201cEffects of SGLT 1-2 Inhibitor Sotagliflozin on Symptoms, Physical &hellip; Continue reading \"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-20T13:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology","datePublished":"2023-02-20T13:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/"},"wordCount":847,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/","name":"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=","datePublished":"2023-02-20T13:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjA0MSM1NDE2OTMxIzIwMDM5Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiologys-72nd-annual-scientific-session-together-with-world-heart-federations-world-congress-of-cardiology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732730"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732730\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}